James E. Langston’s practice focuses on public and private merger and acquisition transactions.

Jim also provides advice regarding governance matters and the fiduciary duties of officers and directors to companies and their boards. 

In 2016, Law360 named Jim one of its “Rising Stars” for his work on some of the largest and most high-profile M&A transactions in recent years. Jim was also named a Next Generation M&A Lawyer by Legal 500 U.S.

Jim joined the firm in 2011 and became a partner in 2015.

Notable Experience

  • Songa Offshore in its pending $3.8 billion combination with Transocean.

  • RCN Communications in its pending $2.3 billion acquisition of Wave Broadband.

  • Allergan in its announced $160 billion merger with Pfizer, the $40.5 billion sale of its global generics pharmaceuticals business to Teva and its $2.1 billion acquisition of Kythera Biopharmaceuticals.

  • Actavis in its $70 billion white knight acquisition of Allergan.

  • Suntory Holdings in its $16 billion acquisition of Beam.

  • Westlake Chemical Corporation in its unsolicited proposal to acquire Axiall Corporation and related proxy contest and the resulting $3.8 billion negotiated acquisition.

  • Surgical Care Affiliates in its $3.5 billion merger with Optum, a subsidiary of UnitedHealth Group.

  • TPG Capital in various transactions, including: its recapitalization of Creative Artists Agency; its $2.25 billion acquisition of RCN Telecommunications and Grande Communications; its recapitalization of RentPath, including the sale of a significant equity stake in RentPath to Providence Equity Partners; its $1.7 billion acquisition of Savers; and its $525 million acquisition of PRIMEDIA.

  • Warburg Pincus in numerous matters, including its acquisition of Universal Services of America, its acquisition of Wencor Group, its acquisition of Gabriel Brothers Inc. and its acquisition of Duravant. 

  • GlaxoSmithKline in its unsolicited tender offer to acquire Human Genome Sciences and the resulting $3.6 billion negotiated acquisition.

  • Biomet and its private equity consortium owners — Blackstone, Goldman Sachs PIA, KKR and TPG — in Biomet’s $13.35 billion cash and stock merger with Zimmer Holdings; and in its acquisition of the global trauma business of DePuy Orthopaedics.

  • Bausch + Lomb and Warburg Pincus in the $8.7 billion sale of Bausch + Lomb to Valeant Pharmaceuticals.

  • Neiman Marcus, TPG Capital and Warburg Pincus in the $6 billion sale of Neiman Marcus to Ares Management and CPPIB.

  • Lafarge in various divestitures in connection with its pending €40 billion merger of equals with Holcim.

  • Medtronic in its $49.9 billion acquisition of Covidien.

  • Acadia Healthcare Company in its $1.2 billion acquisition of CRC Health Group.

  • Danfoss A/S in its going private acquisition of Sauer-Danfoss.

  • Conversus Capital L.P. in the $1.4 billion sale of its portfolio of PE fund interests to an affiliate of HarbourVest Partners LLC.

  • GT Nexus in its $675 million acquisition by Infor.

  • Universal Services in numerous matters, including: its merger of equals with Allied Barton and its $131 million acquisition of the security business of ABM.

See More


Assessing Financial Advisor Compensation Disclosure Following Vento v. CurryCleary M&A and Corporate Governance Watch Blog (April 10, 2017)